Based on the Neurobo Pharmaceuticals stock forecast from 1 analysts, the average analyst NRBO stock price target price for Neurobo Pharmaceuticals Inc is $16 over the next 12 months. Neurobo Pharmaceuticals Inc’s average analyst rating is a Buy . Stock Target Advisor’s own stock analysis of NRBO stock forecast is Bearish, which is based on 1 positive signal and 5 negative signals. At the last closing, Neurobo Pharmaceuticals stock price was USD 20.79. Neurobo Pharmaceuticals stock price has changed by -9.11% over the past week, +20.41% over the past month and -82.59% over the last year.
About Neurobo Pharmaceuticals Inc. (NRBO:NSD):
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
What we like:
Superior Earnings Growth:
NRBO stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What we don’t like:
Low market capitalization:
NRBO stock is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Poor risk adjusted returns:
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns, the returns are unpredictable. Proceed with caution.
Below median dividend returns:
The average income yield of NRBO stock over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow:
The company had negative total free cash flow in the most recent four quarters.
Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.